Anti-CD20-antilichaam (mAb 1.5.3)

Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies[1].

922534-56-3

12352203

Apoptosis; CD20

Apoptosis; Immunology/Inflammation

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

[1]Bornstein, G. G., et al., (2010) . Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational new drugs, 28 (5), 561–574.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991547/

Inhibitory Antibodies

No Development Reported